Abstract |
An open study was made of 25 patients with severe, recalcitrant psoriasis treated with azaribine (6-azauridine triacetate). Most patients received 125 mg/kg/day for a period of 8 weeks. A good to excellent response with 60-100% clearing of lesions was observed in 14 patients and a fair response with 40-60% improvement in another 6 patients. Thus 20 patients (80% of the series) exhibited a favorable clinical response. 16 of these 20 patients relapsed to approximately pretreatment status within 1 month after stopping therapy. The most frequently observed side-effects were mild reversible anemia, fatigue and mild transient gastrointestinal symptons. 8 patients (32% of the series) exhibited sufficient toxicity to necessitate the discontinuance of therapy. 1 patient experienced an unexplained femoral arterial thrombotic episode while on the drug. Azaribine may find a place in the therapy of severe psoriasis particularly in patients with hepatic disease. However, further studies of its potential for toxicity are indicated.
|
Authors | D G Deneau, E M Farber |
Journal | Dermatologica
(Dermatologica)
Vol. 151
Issue 3
Pg. 158-63
( 1975)
ISSN: 0011-9075 [Print] Switzerland |
PMID | 1243822
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Aged
- Azauridine
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Drug Evaluation
- Female
- Humans
- Male
- Middle Aged
- Psoriasis
(drug therapy)
|